LAB International completes patient enrollment in asthma trial

By Elaine Rigoli

Tampa, Fla., Aug. 9 - LAB International, Inc. has completed patient enrollment in its 12-patient LAB CGRP phase 2a asthma trial.

The company said no serious adverse events have been reported in any of the patients dosed.

The company expects study results by the end of the third quarter.

The objectives of the randomized, double blind, cross-over phase 2 study were to investigate the protective efficacy of LAB CGRP on metacholine induced bronchial hyper-responsiveness in adult patients with mild to moderate asthma, to compare this efficacy to salbutamol and a placebo and to evaluate the safety and tolerability of LAB CGRP in asthma patients.

LAB is an integrated drug-development company based in Laval, Quebec.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.